Evidence map›Paper›PMID 29377235›Full record

ArticleAlimentary pharmacology & therapeutics2018

Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.

B Christensen, D Micic, P R Gibson, A Yarur, E Bellaguarda, P Corsello, J N Gaetano, J Kinnucan, V L Rao, S Reddy and 3 more

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 4 pooled it
6.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Primary sclerosing cholangitis.Nature reviews. Disease primers · 2025
    Review
  9. Review
  10. Current Therapeutics in Primary Sclerosing Cholangitis.Journal of clinical and translational hepatology · 2023
    Review
  11. The microbiota and the gut-liver axis in primary sclerosing cholangitis.Nature reviews. Gastroenterology & hepatology · 2023
    Review
  12. Article
  13. Positioning biologics in the treatment of IBD: A practical guideCurrent research in pharmacology and drug discovery · 2022
    Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

B ChristensenAlfred Hospital and Monash University, Melbourne, Australia.ORCID 0000-0002-8746-4275
D MicicNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
P R GibsonAlfred Hospital and Monash University, Melbourne, Australia.
A YarurDivision of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI, USA.
E BellaguardaNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
P CorselloUniversity of Michigan Health System, Ann Arbor, MI, USA.
J N GaetanoUniversity of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA.
J KinnucanUniversity of Michigan Health System, Ann Arbor, MI, USA.
V L RaoUniversity of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA.
S ReddyNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
S SinghDivision of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI, USA.
J PekowUniversity of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA.
D T RubinUniversity of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA.
University of Chicago · USNorthwestern University · USMedical College of Wisconsin · USMichigan Medicine · USMonash University · AUThe Royal Melbourne Hospital · AU

Funding

ULTRASTRUCTURE AND CYTOMORPHOLOGY COREP30DK042086 · NIDDK · UNIVERSITY OF CHICAGO · PI ABADIE, VALERIE · 1990 to 2025
$29.8M
Novel microRNA regulatory networks predictive of colon carcinogenesis in IBDK08DK090152 · NIDDK · UNIVERSITY OF CHICAGO · PI PEKOW, JOEL · 2012 to 2016
$732k
NIDDK NIH HHS K08 DK090152NIDDK NIH HHS P30 DK042086
6 · The paper itself

Abstract

backgroundBlocking of lymphocyte trafficking to bile ducts is a potential mechanism to alter the disease course of patients with primary sclerosing cholangitis (PSC).

aimTo describe the effect of the α

methodsThis is a retrospective multi-centre study of adult patients with a diagnosis of both IBD and PSC. The primary outcome was change in serum alkaline phosphatase level at weeks 14 and 30. Secondary outcomes included changes in other liver biochemistries and in clinical outcomes for the bowel disease. A safety analysis for adverse events was performed.

resultsThirty-four patients (16 Crohn's disease, 18 ulcerative colitis) were included. Nine (26%) had a history of liver transplant. Median follow-up on vedolizumab was 9 months (IQR: 7-16). There was no overall change in serum alkaline phosphatase level with vedolizumab therapy (median 268 [IQR: 105-551] IU/L at baseline versus 249 [IQR: 183-634] IU/L, P = 0.99 at week 30). No significant changes in other liver biochemistries or the Mayo PSC Risk Score were demonstrated at week 30. Clinical remission was achieved at week 30 in 55% of Crohn's disease and 29% of ulcerative colitis patients. Seven (21%) patients ceased vedolizumab; six patients stopped therapy due to persistent IBD activity and one for worsening of liver biochemistries.

conclusionVedolizumab treatment in patients with PSC and IBD did not improve liver biochemistry but was associated with improvement in bowel disease and a favourable safety profile.

Indexed as

AdolescentAdultAntibodies, Monoclonal, HumanizedCholangitis, SclerosingDisease ProgressionFemaleHumansInflammatory Bowel DiseasesLiverLiver Function TestsMaleMiddle AgedRetrospective StudiesTreatment OutcomeYoung AdultAntibodies, Monoclonal, Humanizedvedolizumab

Identifiers

PMID29377235
PMCPMC5821055
OpenAlexW2794344940

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.